"This promising new study on molecular breast imaging provides encouraging data for millions of women and families who are impacted by breast genus Cancer and sheds light on potential new diagnostic approaches for finding tumors in women world Health Organization have impenetrable breast tissue, which can confound mammograms," stated Don Kiepert, president and chieftain executive officer of Lantheus Medical Imaging. "We are proud to supply the imaging broker for this important clinical effort. Breast cancer is a crushing disease and we recognize how important and valuable early spying is for women."
About Cardiolite� Breast Imaging
This imaging test is ill-used to assist in the evaluation of breast lesions in some women wHO have had an abnormal mammogram, or who have a palpable breast mass. The imaging test is not used for showing, or in place of a mammogram. In this test, a woman receives an shot of a small amount of a short-lived radioactive substance called Cardiolite�, which is interpreted up by cancer cells, and a gamma tv camera is put-upon to prevail images of the breasts.
About Cardiolite�
Cardiolite�, formerly marketed as Miraluma� for the tit cancer tomography indication, is FDA-approved for planar imaging as a second melody diagnostic drug after mammography to attend to in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Cardiolite� is not indicated for breast crab screening, or to reassert the presence or absence of a malignancy, and is non an alternative to biopsy. Cardiolite� is also indicated for sleuthing coronary arteria disease by localizing myocardial ischemia (reversible defects) and infarction (nonreversible defects), in evaluating myocardial function and developing information for habit in patient management decisions.
Diagnostic predisposition for lesions less than 1cm. decreases. Cardiolite� has been rarely associated with acute wicked allergic events of quincke's edema and nettle rash. The virtually frequently reported adverse events include headache, breast pain (mostly associated with biopsy/surgery), nausea, and abnormal taste and olfactory perception.
About Lantheus Medical Imaging
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medication for the past 50 years, is committed to elevating and investing in the field of diagnostic imaging. The company's proved success in discovering, developing and selling innovative medical imaging agents provides an unparalleled program from which to bring forward breakthrough new tools for the diagnosis and management of disease. The company is home to leading diagnostic imaging brands, including Cardiolite� (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), DEFINITY� Vial For (Perflutren Lipid Microsphere) Injectable Suspension, and TechneLite� (Technetium Tc99m Generator) and has almost 700 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada, and Australia.
Lantheus Medical Imaging
View drug information on Miraluma test.
More info
- Physicians Eager To Increase Their First- And Second-Line Prescriptions For Januvia Over The Next Two Years For The Treatment Of Type 2 Diabetes
- Sexual Activities Other Than Intercourse Carry Risk Of STIs, Study Finds
- Antihypertensive Treatment On Cognitive Functions In Alzheimer’s Disease
- Blood calcium levels may be tipoff for deadly prostate cancer
- Gunman’s rampage shows pitfalls for mentally ill
